Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.…
Wall Street Analysts Think Replimune Group (REPL) Could Surge 29.51%: Read This Before Placing a Bet
Replimune Group (NASDAQ: REPL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 465 employees.
The shares were at 19.07 USD on 20 November 2026, up 122.3% over 52 weeks. Its 52-week range is 1.500 USD to 23.41 USD: the price is 18.5% below the high and 1171.3% above the low.
Its market capitalisation is 1.81B USD.
Replimune Group reports return on equity of -188.9% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 180.64M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Buy; their mean price target of 25.50 USD is 33.7% above the current price. The next earnings report is expected on 3 February 2027.